TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00525291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
Description: In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-biofeedback alone
Description: In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
Study: NCT02561897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT04865848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental local anesthesia
Description: Dental local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental local anesthesia
Description: Dental local anesthesia
Study: NCT00885443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
Study: NCT03701191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted periosteal pedicle flap
Description: The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted periosteal pedicle flap
Description: The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
Study: NCT01353664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
Study: NCT01880853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography
Description: participants were screened by mammography alone every year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: participants were screened by ultrasound alone every year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography and ultrasound
Description: Participants were screened by both mammography and ultrasound every year
Study: NCT03034694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teledermatology consult
Description: teledermatology consult

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: The patient will undergo imaging but this report will not be put into the chart.
Study: NCT02345941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Action Report
Description: Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Action Report
Description: Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Portal
Description: Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Portal
Description: Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
Study: NCT02857322

Intervention type: OTHER
Group type: OTHER
Intervention: Accompanying patient's specific perioperative
Study: NCT00215618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Balloon Therapy
Description: UBT with post procedure curettage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Balloon Therapy
Description: UBT without post procedure curettage
Study: NCT01967043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
Study: NCT02249715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway Multiway deep TMS device (two channels)
Study: NCT04007484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Description: Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
Study: NCT01834495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon expandable stent
Description: provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self expandable stent
Description: provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
Study: NCT01412879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT01859819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT Cytarabine
Study: NCT03399344

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
Study: NCT04163263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-356
Description: topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-356
Description: topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-356
Description: topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel
Study: NCT00393367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg
Description: Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone, prednisone, or methylprednisolone
Description: All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
Study: NCT01412879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT01322828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal bicep tendon reconstruction
Description: Randomized to either a single incision technique or a double incision technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal bicep tendon reconstruction
Description: Randomized to either a single incision technique or a double incision technique.
Study: NCT01445171

Intervention type: DEVICE
Group type: OTHER
Intervention: Aortic Valve Replacement with EDWARDS INTUITY Valve System
Description: Aortic Valve bioprosthesis
Study: NCT03101072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed long antibiotic course of 14 days
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
Study: NCT02713425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entertaining Video Game
Description: Children between 7 \& 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
Study: NCT02131805

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Electronic Skin Surface Brachytherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Study: NCT04019834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regional nerve block with local anesthesia of bupivacaine with steroid
Description: Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo regional nerveblock with normal saline
Description: Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
Study: NCT00665470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks
Study: NCT00963482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural smoking cessation program
Description: It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Autogenic training
Description: Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
Study: NCT04030286

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
Study: NCT03101072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed short antibiotic course of 7 days
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized duration of antibiotic therapy
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
Study: NCT01715844

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: Patients will take 3-gr of L-citrulline/day for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline
Description: Patients will take 3-gr of L-citrulline/day for 7 days
Study: NCT00468715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT02058121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is provided in 12 weekly two hour long sessions in a group setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
Study: NCT02976506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise program
Description: Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical fitness and quality of life
Description: Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
Study: NCT03415230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Description: Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham massage
Description: Sham massage involves only light touch massage in a non systematic way
Study: NCT00390832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
Study: NCT03463330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Description: The Qigong exercise is a series of mild exercise movements.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mild body exercise
Description: Participants will be taught of series of similar movements to the Qigong exercise.
Study: NCT00142506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate and questionaires
Description: Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets and questionaires
Description: Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Study: NCT02807077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
Study: NCT03217162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant combined with mechanical ventilation (MV)
Description: surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation (MV)
Description: mechanical ventilation (MV) is given to the infant with ARDS